One in five people suffer from some form of depression or anxiety, which has been exacerbated by the pandemic. Barriers and limited access to care, coupled with a shortage of mental health physicians has helped spur tremendous growth (and record investments) in digital therapeutics, which is not only filling the gap, but increasingly proving to be a viable option. Chris Wasden, Head of Digital Therapeutics at Happify Health discusses these trends and the launch of Ensemble, a first-of-its kind prescription digital therapy solution that leverages a myriad of targeted AI, gamification and 100+ Cognitive-Behavioral Therapy (CBT) and mindfulness interventions that was brought to market under the FDA’s Covid Emergency Authorization.
As Head of HappifyDTx and Board Member of the Digital Therapeutic Alliance (DTA), Chris is leading the effort to bring Happify’s platform to the pharmaceutical and healthcare industry. Recently he was a professor at the University of Utah and served as Executive Director of the Sorenson Center for Discovery & Innovation, a digital health game incubator. He is the co-author of two books on innovation, creativity, and leadership: Tension – The Energy of Innovation; and Solving for Why – Change Your Identity, Change Your Future. He is the named inventor on 12 issued patents, has been a founding leader in 10 startups, and has held leadership positions at JP Morgan and PwC. He holds a doctorate from George Washington University in Human and Organizational Learning, and an M.B.A. from UCLA Anderson School.